In contrast, replacing the defective CFTR activity with anionophores would be a novel therapeutic approach for the treatment of CF that is independent of the mutation the patient harbors and, thus, would have a clear advantage over CF therapy using correctors and potentiators of CFTR [9,10,11]. This evidence concerns the gene CFTR and cystic fibrosis.